By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

CureMatch 

6370 Lusk Boulevard
Suite F208
San Diego  California  92121  U.S.A.
Phone: 858-859-2873 Fax: 858-430-5813


SEARCH JOBS

CureMatch™ was founded because we identified the need for improved decision-support within the UCSD Tumor Board. Each of the founders has a personal drive to contribute to the field of Precision Medicine. Cancer has closely impacted each of us and we want to use our scientific, entrepreneurial and financial experience to contribute to the good of the community. We look forward to providing physicians with the means to improve cancer patients’ quality of life.

YEAR FOUNDED:

2015

LEADERSHIP:

CEO and Chairman of the Board: Blaise Barrelet

Co-Founder and CTO: Igor Tsigelny, PhD

Co-Founder & Medical Advisor: Razelle Kurzrock, MD

President & COO: Stephane Richard, PhD

TECHNOLOGY:

Please click here for CureMatch's technology.


Key Statistics


Email: info@curematch.com
Ownership: Private

Web Site: CureMatch
Employees:
Symbol: 
 



Industry
Diagnostics






Company News
Serra Ventures Invests In CureMatch 8/16/2017 8:00:42 AM
CureMatch Announces Pricing For Its Cutting-Edge Combination Therapy Report For Cancer Treatment 5/25/2017 7:43:03 AM
CureMatch Partnering With Patient Power To Educate And Empower Patients And Oncologists Regarding Personalized Cancer Treatments 3/30/2017 10:20:25 AM
CureMatch Launches Decision Support Platform To Harness The Power Of Personalized Medicine In Cancer Care 3/7/2017 11:04:02 AM
CureMatch Launches Decision Support Platform To Harness The Power Of Personalized Medicine In Cancer Care 3/7/2017 7:52:11 AM
CureMatch Announces New Advances In Using Metabolomic Profiling To Distinguish Among Cancer Subtypes 2/24/2017 7:17:43 AM
Study Validates A Core Principle Behind The CureMatch Technology 2/17/2017 8:05:14 AM
CureMatch Announces Publication In Oncoimmunology Of Data Unveiling A Specific Mutagenesis Process Linked To The Response To Immunotherapy In Cancer 2/7/2017 7:24:51 AM
//-->